bluebird bio, Inc. (NASDAQ:BLUE) Receives $5.87 Average PT from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Free Report) have received an average recommendation of “Hold” from the twelve analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the […]

Leave a Reply

Your email address will not be published.

Previous post Sanofi (NASDAQ:SNY) Receives $55.00 Consensus Target Price from Brokerages
Next post Oppenheimer Reaffirms “Market Perform” Rating for A. O. Smith (NYSE:AOS)